Long term HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg and HBcAg mixed with mucoadhesive CVP (CVP-NASVAC) in patients with chronic HBV infection: The results of 48 months follow up

Conference Reports for NATAP

AASLD
The Liver Meeting
November Fri, Nov 10, 2023 - Mon, Nov 14, 2023


Long term HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg and HBcAg mixed with mucoadhesive CVP (CVP-NASVAC) in patients with chronic HBV infection: The results of 48 months follow up

	AASLD 2023 nov 10-14 https://www.aasld.org/the-liver-meeting